DeutschNewstral
Article
bizjournals.com on 2015-09-22 15:01
Durham drug developer gets FDA cash to work on orphan disease drug
Related news
- With eyes on FDA, Durham drug developer tests drug in late-stage trialbizjournals.com
- Durham cancer drug developer sees shares pop 35% on FDA designationbizjournals.com
Lundbeck's Carnexiv gets FDA orphan drug statusdailyherald.com- SA biotech gets FDA orphan drug designationbizjournals.com
- FDA gives Biogen the nod to manufacture MS drug in Durhambizjournals.com
- FDA makes partial clinical hold official for Durham firm's drug candidatebizjournals.com
- Developer of drug for 'devastating' disorder in kids gets good FDA newsbizjournals.com
- Japanese pharma sues Durham drug developerbizjournals.com
- FDA pilot program could help Wave avoid orphan-drug pitfallsbizjournals.com
FDA finalizes guidance on Orphan Drug “sameness” of gene therapiesjdsupra.com
Sapience Therapeutics ST-36 receives orphan drug designation from FDAwestfaironline.com- MProQR shares rises on FDA orphan drug designationmarketwatch.com
FDA approves $2.1M drug for baby diseasenwaonline.com
FDA Approves Drug to Treat Parkinson’s Diseaseexploreclarion.com- MCelgene's rare disease drug gets FDA approvalmarketwatch.com
- Imbrium Therapeutics receives FDA orphan drug designation for biliary tract cancer drugwestfaironline.com
- Annovis Bio seeks orphan drug status from FDA for its lead new drug candidatebizjournals.com
- Durham loses drug developer Scynexis to New Jerseybizjournals.com
- Durham drug developer to raise cash, but dilute shareholders' stakebizjournals.com